• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions

    6/12/25 12:01:00 PM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $INCY alert in real time by email

    SINGAPORE, June 12, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the expansion of its existing supply and distribution agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two additional medicines from its oncology portfolio in Australia, New Zealand and Singapore, with an option to add further countries in the Asia-Pacific region. The expanded agreement will see new therapies axatilimab (registered as Niktimvo® in the United States) and retifanlimab (registered as Zynyz® in the U.S. and European Union) added to the current partnered portfolio of Minjuvi® (tafasitamab) and Pemazyre® (pemigatinib).

    (PRNewsfoto/Specialised Therapeutics)

    Under the terms of the expanded agreement, Incyte will be responsible for the development, manufacture and supply of both axatilimab and retifanlimab to the region, while ST will have responsibility for regulatory, distribution and local marketing and medical affairs related activities.

    ST Chief Executive Officer, Mr Carlo Montagner, welcomed the expansion of the partnership agreement with Incyte, a leading global biopharmaceutical company, and the opportunity to bring these important medicines to eligible patients in the local region.

    "Specialised Therapeutics has partnered with Incyte since 2021 and we are delighted to be extending this successful partnership," he said. "As part of our initial agreement, our teams have worked collaboratively to commercialise Minjuvi, which has been approved for use in Australia, and Pemazyre, which has been approved in Australia and Singapore, and we look forward to expanding the portfolio to help more patients with rare and hard-to-treat conditions."

    "The addition of axatilimab and retifanlimab to the partnership agreement with Incyte recognises our strong track record of working with local stakeholders to bring innovative medicines to patients where unmet medical needs persist, despite the availability of existing treatments," said Mr Montagner. "Our focus will be on seeking regulatory and reimbursement approval for all four medicines in the region, to ensure equitable access to these treatments are available for patients as soon as practicable."

    ST anticipates submitting axatilimab and retifanlimab for local regulatory and reimbursement approval in 2025.

    Incyte CEO, Mr Hervé Hoppenot said the expanded partnership agreement reflected the synergies between the two companies, with a shared goal of improving outcomes for patients with unmet medical needs.

    "We are pleased to extend our partnership with ST to include axatilimab and retifanlimab," he said. "ST has already demonstrated its ability to navigate complex regional regulatory pathways for Minjuvi and Pemazyre, and we look forward to continuing our work together to make these new therapies available for the oncology community in the Asia-Pacific region."

    Axatilimab is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody. It was approved by the US Food and Drug Administration (FDA) in August 2024 as a treatment for adults and children with chronic graft-versus-host disease (GVHD) who have received at least two prior treatments (systemic therapy) and require additional treatment.1 Chronic GVHD usually occurs 3 months after a transplant - typically haematopoietic stem cell or bone marrow transplantation, but occasionally also solid organ transplants - where the donor cells ("graft") attack the graft recipient's cells ("host").2 Chronic GVHD can affect all organs, but commonly impacts the skin, mouth, eyes, lungs, stomach, bowel, and liver.2,3 The Phase II clinical trial for axatilimab involved 79 patients from 13 countries, including Australia and Singapore.4

    Retifanlimab is an intravenous immune checkpoint (PD-1) inhibitor that has been approved in the US in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) and as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression or intolerance to platinum-based chemotherapy.5 Retifanlimab is also approved in the US6 and Europe7 for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). MCC is a rare and aggressive type of skin cancer, that is often difficult to diagnose due to the lack of specific features to distinguish it from other common skin cancers.8 Australia has the highest incidence of MCC in the world.9 The pivotal Phase II clinical trial of retifanlimab in MCC enrolled 101 chemotherapy-naïve patients from 12 countries, including Australia.10 In addition to MCC, retifanlimab, in combination with chemotherapy, is currently being investigated as a potential therapeutic option in other hard-to-treat cancers, including metastatic non-small cell lung cancer (NSCLC).

    Ends.

    About Specialised Therapeutics

    Founded in 2007, Specialised Therapeutics is the region's largest independent specialty pharmaceutical company, providing new therapies and technologies to patients in Australia, New Zealand and across Southeast Asia. Headquartered in Singapore, ST partners with global pharmaceutical, biotech and diagnostic companies to bring novel healthcare opportunities to patients who are impacted by a range of diseases. ST has built a strong track record of success, navigating complex regulatory, reimbursement and commercialisation environments in its diverse regions. The ST mission is to provide specialty therapies where there is an unmet need. The company's broad therapeutic portfolio currently includes novel agents in oncology, haematology, CNS, neurology, endocrinology, ophthalmology and supportive care, although it is not confined to these areas. ST is a member of the World Orphan Drug Alliance (WODA).

    Additional information can be found at www.stbiopharma.com

    About axatilimab (Niktimvo®) 

    Axatilimab-csfr (registered as Niktimvo® in the United States) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the US for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and paediatric patients weighing at least 40 kg (88.2 lbs).

    In 2016, Syndax licensed exclusive worldwide rights to develop and commercialise axatilimab from UCB. In September 2021, Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialisation license agreement for axatilimab in chronic GVHD and any future indications.

    Axatilimab is being studied in frontline combination trials in chronic GVHD – a Phase 2 combination trial with ruxolitinib (NCT06388564) and a Phase 3 combination trial with steroids (NCT06585774) are underway. Axatilimab is also being studied in an ongoing Phase 2 trial in patients with idiopathic pulmonary fibrosis (NCT06132256).

    Niktimvo is a trademark of Incyte.

    All other trademarks are the property of their respective owners.

    About retifanlimab (Zynyz®) 

    Retifanlimab-dlwr (registered as Zynyz® in the United States and European Union) is a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), indicated in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) and as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression or intolerance to platinum-based chemotherapy in the U.S.

    Zynyz is also indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) in the US. This indication is approved under accelerated approval based on tumour response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

    Zynyz is marketed by Incyte in the US. In 2017, Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc. for global rights to retifanlimab.

    Zynyz is a registered trademark of Incyte.

    References:

    1. US FDA. FDA approves axatilimab-csfr for chronic graft-versus-host disease, 14 Aug 2024. Available at: https://www.fda.gov/‌ drugs/resources-information-approved-drugs/fda-approves-axatilimab-csfr-chronic-graft-versus-host-disease [Accessed Mar 2025].
    2. The Australasian College of Dermatologists. A-Z of Skin: Graft Versus Host Disease, Nov 2020. Available at: https://www.dermcoll.edu.au/wp-content/uploads/2022/03/Graft-Versus-Host-Disease-A-Z-of-Skin.pdf [Accessed Mar 2025].
    3. Leukaemia Foundation Australia. Factsheet: Graft versus host disease, 24 May 2024. Available at: https://www.leukaemia.org.au/wp-content/uploads/2022/11/Factsheet_Graft-Versus-Host-Disease_Leukaemia-Foundation.pdf [Accessed Mar 2025].
    4. ClinicalTrials.gov. A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) (AGAVE-201); NCT04710576. Available at: https://clinicaltrials.gov/study/NCT04710576 [Accessed Mar 2025].
    5. FDA approves retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-retifanlimab-dlwr-carboplatin-and-paclitaxel-and-single-agent-squamous-cell-carcinoma. [Accessed May 2025]
    6. US FDA. FDA grants accelerated approval to retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinoma, 22 Mar 2023. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-retifanlimab-dlwr-metastatic-or-recurrent-locally-advanced-merkel [Accessed Mar 2025].
    7. European Medicines Agency (EMA). Zynyz (retifanlimab): Marketing Authorisation in the European Union (EU), 19 Apr 2024. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/zynyz [Accessed Mar 2025].
    8. NeuroEndocrine Cancer Australia. Merkel Cell Carcinoma: The Facts, 19 Nov 2023. Available at: https://neuroendocrine.‌ org.au/what-are-nets/merkel-cell-carcinoma/ [Accessed Mar 2025].
    9. The Australasian College of Dermatologists. A-Z of Skin: Merkel cell carcinoma, Oct 2024. Available at: https://www.dermcoll.edu.au/‌ atoz/merkel-cell-carcinoma/ [Accessed Mar 2025].
    10. Grignani G, et al. Updated Results From POD1UM-201: A Phase 2 Study of Retifanlimab in Patients With Advanced or Metastatic Merkel Cell Carcinoma. Presented at the European Society for Medical Oncology Congress 2023, Madrid, Spain; 20-24 October 2023.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/specialised-therapeutics-expands-partnership-with-incyte-to-include-two-additional-therapies-for-hard-to-treat-conditions-302479723.html

    SOURCE Specialised Therapeutics

    Get the next $INCY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $INCY

    DatePrice TargetRatingAnalyst
    6/16/2025$107.00Hold → Buy
    Stifel
    3/18/2025Buy → Neutral
    Guggenheim
    3/18/2025Outperform → Mkt Perform
    William Blair
    12/17/2024$77.00Neutral
    UBS
    10/29/2024$68.00 → $90.00Neutral → Buy
    BofA Securities
    10/1/2024$84.00Outperform
    Wolfe Research
    9/18/2024$83.00 → $74.00Buy → Hold
    Truist
    7/2/2024$52.00 → $48.00Market Perform → Underperform
    BMO Capital Markets
    More analyst ratings

    $INCY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

      – Total revenues of $1,216 million in the second quarter (Q2'25) (+16% Y/Y); total product revenues of $1,059 million in Q2'25 (+17%Y/Y) – Jakafi® (ruxolitinib) net product revenues of $764 million in Q2'25 (+8% Y/Y); raising full year 2025 guidance to a new range of $3,000 - $3,050 million [previously $2,950 - $3,000 million] – Opzelura® (ruxolitinib) cream net product revenues of $164 million in Q2'25 (+35% Y/Y) – Niktimvo™ (axatilimab-csfr) net product revenues of $36 million in the second quarter, demonstrating strong commercial execution; raising full year 2025 Other Oncology guidance to a new range of $500 - $520 million [previously $415 - $455 million] – Zynyz® (retifanlimab-

      7/29/25 7:00:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025

      - Mini oral presentation to highlight initial Phase 1 data of INCA33890, a promising TGFβR2×PD-1-directed bispecific antibody, in patients with advanced or metastatic solid tumors - Oral presentation to feature initial data of INCB161734, a novel, selective and orally bioavailable inhibitor of G12D-mutated KRAS, in patients with advanced or metastatic solid tumors with KRASG12D mutations Incyte (NASDAQ:INCY) today announced that the Company will present key data from its oncology portfolio at the upcoming European Society of Medical Oncology (ESMO) Congress 2025, to be held October 17-21 in Berlin. "We're looking forward to presenting the latest findings across our oncology portfolio

      7/24/25 5:02:00 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte to Report Second Quarter Financial Results

      Incyte (NASDAQ:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 29, 2025. The schedule for the press release and conference call/webcast is as follows: Q2 2025 Press Release: July 29, 2025 at 7:00 a.m. ET Q2 2025 Conference Call: July 29, 2025 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13754581 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-6

      7/10/25 8:00:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Incyte upgraded by Stifel with a new price target

      Stifel upgraded Incyte from Hold to Buy and set a new price target of $107.00

      6/16/25 7:42:04 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte downgraded by Guggenheim

      Guggenheim downgraded Incyte from Buy to Neutral

      3/18/25 7:52:49 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte downgraded by William Blair

      William Blair downgraded Incyte from Outperform to Mkt Perform

      3/18/25 7:52:29 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    SEC Filings

    See more
    • SEC Form 10-Q filed by Incyte Corp.

      10-Q - INCYTE CORP (0000879169) (Filer)

      7/29/25 4:01:59 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - INCYTE CORP (0000879169) (Filer)

      7/29/25 7:06:23 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 144 filed by Incyte Corp.

      144 - INCYTE CORP (0000879169) (Subject)

      7/21/25 4:01:11 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Leadership Updates

    Live Leadership Updates

    See more
    • Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire

      - Three-decade industry leader, former CEO of Karuna and Anthos and Chief Commercial Officer of Allergan, Bill Meury, joins Incyte as President and CEO - Hervé Hoppenot to retire after 11 years of leading Incyte through major expansion - Julian Baker elected Chairman of the Board of Directors Incyte (NASDAQ:INCY) today announced that the Company's Board of Directors has unanimously appointed Bill Meury as President and Chief Executive Officer (CEO) and a member of the Company's Board of Directors, effective immediately. Bill Meury succeeds Hervé Hoppenot who will retire from the Company after 11 years of service. Mr. Hoppenot will serve as an advisor to the CEO and will remain as a

      6/26/25 7:30:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board

      Mechelen, Belgium; 12 June 2023, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that during its meeting of 12 June 2023, the Board of Directors co-opted Dr. Susanne Schaffert as non-executive independent Director. Dr. Schaffert replaces Dr. Rajesh Parekh who stepped down on 10 June 2023. After an extraordinary 27-year career at Novartis in various global roles, including commercialization, market access, investor relations, business development & licensing, acquisitions and company integration, Dr. Schaffert retired in 2022 as President of Novartis Oncology and Member of the Novartis Executive Committee. In that role, Dr. Schaffert ran a global $15 billion business acr

      6/12/23 4:01:00 PM ET
      $GLPG
      $INCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
    • Incyte Names New Member to Its Board of Directors

      Incyte (NASDAQ:INCY) announces the appointment of Susanne Schaffert, Ph.D., as a new member of its Board of Directors. "On behalf of the Incyte Board of Directors, I am happy to welcome Susanne. Her extensive commercial, development and industry experience will greatly complement our Board and we look forward to Susanne's contributions to our continued growth and future success," said Hervé Hoppenot, Chief Executive Officer, Incyte. "I am very excited for the opportunity to join the Incyte Board of Directors and helping the organization in its commitment to leading scientific innovation and developing new medicines for patients in need. I look forward to being part of this dynamic Company

      10/4/22 8:00:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Financials

    Live finance-specific insights

    See more
    • Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

      – Total revenues of $1,216 million in the second quarter (Q2'25) (+16% Y/Y); total product revenues of $1,059 million in Q2'25 (+17%Y/Y) – Jakafi® (ruxolitinib) net product revenues of $764 million in Q2'25 (+8% Y/Y); raising full year 2025 guidance to a new range of $3,000 - $3,050 million [previously $2,950 - $3,000 million] – Opzelura® (ruxolitinib) cream net product revenues of $164 million in Q2'25 (+35% Y/Y) – Niktimvo™ (axatilimab-csfr) net product revenues of $36 million in the second quarter, demonstrating strong commercial execution; raising full year 2025 Other Oncology guidance to a new range of $500 - $520 million [previously $415 - $455 million] – Zynyz® (retifanlimab-

      7/29/25 7:00:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte to Report Second Quarter Financial Results

      Incyte (NASDAQ:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 29, 2025. The schedule for the press release and conference call/webcast is as follows: Q2 2025 Press Release: July 29, 2025 at 7:00 a.m. ET Q2 2025 Conference Call: July 29, 2025 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13754581 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-6

      7/10/25 8:00:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

      Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy cells and restoring normal blood cell production In high-risk patients with essential thrombocythemia (ET) with a CALR mutation (mutCALR), 86% of INCA033989-treated patients at doses 400 mg and above achieved a complete or partial hematologic response with the majority (82%) realizing a complete response A reduction in peripheral blood mutCALR variant allele frequency (VAF) was observed in 89% of evaluable patients correlating with hematologic response Initial results demonstrate a favorable safety profile – no dose limiting toxicit

      6/15/25 3:15:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Incyte Corp.

      SC 13G - INCYTE CORP (0000879169) (Subject)

      10/17/24 9:39:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Incyte Corp.

      SC 13D/A - INCYTE CORP (0000879169) (Subject)

      6/14/24 6:23:05 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D/A filed by Incyte Corp. (Amendment)

      SC 13D/A - INCYTE CORP (0000879169) (Subject)

      5/13/24 6:06:33 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for JAKAFI issued to INCYTE CORP

      Submission status for INCYTE CORP's drug JAKAFI (SUPPL-25) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/27/2021. Application Category: NDA, Application Number: 202192, Application Classification: Labeling

      9/28/21 5:20:01 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • FDA Approval for JAKAFI issued to INCYTE CORP

      Submission status for INCYTE CORP's drug JAKAFI (SUPPL-23) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/22/2021. Application Category: NDA, Application Number: 202192, Application Classification: Efficacy

      9/23/21 5:11:12 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • FDA Approval for OPZELURA issued to INCYTE CORP

      Submission status for INCYTE CORP's drug OPZELURA (ORIG-1) with active ingredient RUXOLITINIB has changed to 'Approval' on 09/21/2021. Application Category: NDA, Application Number: 215309, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

      9/22/21 11:16:23 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & Chief Medical Officer Stein Steven H sold $251,786 worth of shares (3,706 units at $67.94), decreasing direct ownership by 3% to 102,886 units (SEC Form 4)

      4 - INCYTE CORP (0000879169) (Issuer)

      7/23/25 3:56:25 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • EVP & General Manager US Flannelly Barry P sold $91,602 worth of shares (1,340 units at $68.36), decreasing direct ownership by 4% to 35,149 units (SEC Form 4)

      4 - INCYTE CORP (0000879169) (Issuer)

      7/17/25 4:06:01 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • EVP, GMAPPS Iyengar Vijay K sold $67,198 worth of shares (983 units at $68.36), decreasing direct ownership by 2% to 40,540 units (SEC Form 4)

      4 - INCYTE CORP (0000879169) (Issuer)

      7/17/25 4:05:27 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care